PHASE 1/1B TRIAL OF FC-ENGINEERED ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (2141-V11) INFUSED WITH D2C7-IT IN ENHANCING DISEASE BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (RMG)

被引：0

作者：

Desjardins, Annick ^{[1
]}

Chandramohan, Vidya ^{[2
]}

Landi, Daniel ^{[2
]}

Peters, Katherine ^{[3
]}

Johnson, Margaret O. ^{[4
]}

Low, Justin ^{[2
]}

Khasraw, Mustafa ^{[1
]}

Threatt, Stevie ^{[3
]}

Bullock, Chevelle ^{[3
]}

Herndon, James ^{[5
]}

Lipp, Eric ^{[6
]}

Friedman, Allan ^{[7
]}

Friedman, Henry ^{[6
]}

Ashley, David ^{[8
]}

Osorio, Juan ^{[9
]}

Ravetch, Jeffrey ^{[9
]}

Bigner, Darell ^{[3
]}

机构：

[1] Duke Brain Tumor Immunotherapy Program, Durham, NC USA

[2] Duke Univ, Durham, NC USA

[3] Duke Univ, Med Ctr, Durham, NC USA

[4] Duke Univ, Sch Med, Preston Robert Tisch Brain Tumor Ctr, Dept Neurosurg, Durham, NC USA

[5] Duke Canc Inst, Dept Biostat, Durham, NC USA

[6] Preston Robert Tisch Brain Tumor Ctr, Dept Neurosurg, Durham, NC USA

[7] Duke Univ, Dept Neurosurg, Durham, NC USA

[8] Preston Robert Tisch Brain Tumor Ctr, Durham, NC USA

[9] Rockefeller Univ, New York, NY USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CTIM-09

引用

页数：2